{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Cjc-1295",
    "short_name": "CJC-1295",
    "aliases": [
      "cjc",
      "CJC-1295 (no DAC)",
      "CJC-1295 DAC",
      "GHRH analog"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Investigational peptide discussed as a GHRH analog affecting GH/IGF signaling. Not an FDA-approved therapeutic drug."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-17",
      "human_use_note": "CJC-1295 is not an approved therapeutic drug. Human evidence exists for GH/IGF changes in controlled settings, but long-term safety and outcome evidence for enhancement use is limited."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 7,
      "severity": "high",
      "likelihood": "possible",
      "evidence_grade": "human_interventional",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Manipulating GH/IGF axis has systemic downstream effects (glucose handling, edema, blood pressure, sleep). Human studies show endocrine effects; however, long-term outcomes and safety in non-medical enhancement contexts are uncertain. Adolescents are higher consequence risk due to developing endocrine setpoints.",
      "risk_score": 7
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "moderate",
          "evidence_grade": "human_interventional",
          "text": "CJC-1295 is a growth hormone releasing hormone (GHRH) analog discussed for increasing growth hormone and IGF-1 signaling. Controlled human research has reported endocrine changes, but long-term clinical outcomes and safety for enhancement use remain uncertain.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "varies",
          "unit": "study-dependent",
          "min": null,
          "max": null,
          "frequency": "varies",
          "duration": "varies",
          "population_group": "general",
          "notes": "Descriptive only. This app does not provide protocols. Not instructions.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "developmental_risk_block": [
        {
          "title": "Developmental / Adolescent risk",
          "population_group": "adolescent",
          "confidence": "moderate",
          "evidence_grade": "unknown",
          "text": "Because CJC-1295 targets GH/IGF signaling, adolescents and still-developing endocrine systems should treat uncertainty as a meaningful risk. Long-term setpoint changes are not well characterized.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a growth hormone releasing hormone (GHRH) analog discussed for increasing growth hormone and IGF-1 signaling",
        "controlled human research has reported endocrine changes, but long-term clinical outcomes and safety for enhancement use remain uncertain",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "CJC-1295 increases growth hormone and IGF-1 in healthy adults (human interventional study)",
        "source_type": "pubmed",
        "source_id": "16352683",
        "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/",
        "published_date": "2006-01-01",
        "evidence_grade": "human_interventional",
        "notes": "Interventional human research reporting GH/IGF-1 changes. Does not establish long-term enhancement outcomes or safety in non-medical use contexts.",
        "year": 2006
      }
    ],
    "changelog": [
      {
        "date": "2026-01-17",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for CJC-1295",
        "detail": "Added GHRH analog entry with human endocrine evidence and strong uncertainty framing; flagged developmental risk due to endocrine setpoint concerns.",
        "evidence_refs": [
          "E1"
        ]
      }
    ],
    "meta": {
      "appears_in_blends": [
        "cjc-ipamorelin"
      ]
    },
    "topics": {
      "primary": [
        "topic_muscle_recovery",
        "topic_hormonal_endocrine"
      ]
    },
    "slug": "cjc-1295"
  },
  "canonical_name": "Cjc-1295",
  "interactions": {
    "drug_classes": [],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "schema_version": "practical_block_v1",
    "benefits": [
      "Interest in increased GH/IGF-1 signaling (body composition / recovery discussions)",
      "Sleep and “recovery quality” anecdotes in fitness communities",
      "Often discussed as part of GH-axis “stacking” (conceptual, not a protocol)"
    ],
    "side_effects_common": [
      "Water retention / puffiness (reported in GH-axis discussions)",
      "Increased appetite or changes in hunger (variable reports)",
      "Fatigue or headache (nonspecific, inconsistently reported)"
    ],
    "side_effects_serious": [
      "Signs of glucose intolerance (unusual thirst/urination, unexplained fatigue) — seek medical evaluation",
      "Rapid swelling, shortness of breath, or chest pain (seek urgent care)",
      "Severe allergic reaction (hives, facial swelling, trouble breathing)"
    ],
    "who_should_be_cautious": [
      "People with diabetes or prediabetes, or strong family history of metabolic disease",
      "Active malignancy or cancer history where growth signaling is a concern (requires clinician discussion)",
      "Pregnancy/breastfeeding (avoid due to uncertainty)",
      "Adolescents (avoid: growth axis manipulation + long-term uncertainty)"
    ],
    "bottom_line": "CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH). In real-world wellness and bodybuilding circles it’s discussed for GH/IGF-1 elevation, recovery, and body composition—but the evidence base is limited, and most use happens outside regulated medical systems."
  }
}
